AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3453431
Drug: Nicergoline (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicergoline (30 mg twice a day) for at least 6 months (open design for PAD patients)
Trial: 24825805
Drug: Intramuscular meperidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular meperidine injection administered 30 minutes before the biopsy
Trial: 24825805
Drug: Periprostatic nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periprostatic nerve block (PNB) by injection 10 minutes prior to the prostate biopsy
Trial: 16623075
Drug: Irbesartan/HCTZ 150/12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan/HCTZ 150/12.5 mg (8 weeks)
Trial: 16623075
Drug: Irbesartan/HCTZ 300/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan/HCTZ 300/25 mg (8 weeks)
Trial: 18681815
Drug: Irbesartan/HCTZ (overall
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan/HCTZ (overall treatment)
Trial: 14514935
Drug: Self-management advice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-management advice from the pharmacist with weekly telephone follow up for 3 months
Trial: 6536506
Drug: Postoperative continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative continuous epidural morphine (group C)
Trial: 6536506
Drug: Oral phenoxybenzamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral phenoxybenzamine 10 mg (group D)
Trial: 6536506
Drug: Postoperative mild
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative mild analgesics (group B)
Trial: 30272094
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of MI and Omega-3 supplementation
Trial: 17974883
Drug: Lyophilized bone
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lyophilized bone chips with platelet gel (Group A)
Trial: 17974883
Drug: Lyophilized bone
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lyophilized bone chips with platelet gel and bone marrow stromal cells (Group B)
Trial: 17974883
Drug: Lyophilized bone
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lyophilized bone chips without gel (Group C)
Trial: 12581547
Drug: Ciprofloxacin QD
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin QD 500 mg once daily for 3 days
Trial: 12581547
Drug: Ciprofloxacin BID
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin BID 250 mg twice daily for 3 days
Trial: 8665884
Drug: Bupivacaine 5
RxNorm normalized name: Sure-Amp BUPivacaine 5 MG/ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 5 mL
Trial: 8665884
Drug: Bupivacaine 5
RxNorm normalized name: Sure-Amp BUPivacaine 5 MG/ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 5 mL plus Thiomucase 10 U mL‐1
Trial: 8665884
Drug: Bupivacaine 9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 9 mL
Trial: 8665884
Drug: Bupivacaine 9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 9 mL plus Thiomucase 10 U mL‐1
Trial: 897173
Drug: Simethicone preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simethicone preparation
Trial: 897173
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no simethicone preparation)
Trial: 2766870
Drug: Perioperative antibiotic
RxNorm normalized name: ENSURE SURGERY PERIOPERATIVE KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative antibiotic prophylaxis
Trial: 30506144
Drug: Cinacalcet (starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinacalcet (starting dose ≤ 0.20 mg/kg)
Trial: 28456603
Drug: Lidocaine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (2 mg kg−1) IV over 1 minute
Trial: 25056999
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (1 hour)
Trial: 21315207
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg RB006
Trial: 21315207
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin or low molecular heparin
Trial: 16875447
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (identical treatment from a dummy cluster)
Trial: 9410047
Drug: Dirithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dirithromycin (500 mg/day over 5 days)
Trial: 9410047
Drug: Diacetylmidecamycin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diacetylmidecamycin (600 mg, twice daily over 7 days)
Trial: 9536227
Drug: Calcipotriol ointment
RxNorm normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol ointment (50 micrograms/g) applied twice daily
Trial: 4047707
Drug: Acetaminophen plus
RxNorm normalized name: acetaminophen / hydrocodone Oral Capsule [Ceta Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen plus codeine, 300 mg plus 30 mg
Trial: 30799926
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (ITT and CC populations)
Trial: 27423320
Drug: Intervention participants
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intervention participants who kept coach visits, attended group sessions, and used patches
Trial: 24685561
Drug: 10-mg cocaine
RxNorm normalized name: cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-mg cocaine units
Trial: 24685561
Drug: 0-mg cocaine
RxNorm normalized name: cocaine 0.1 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0-mg cocaine units
Trial: 22066530
Drug: Standard triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard triple therapy (20 mg of rabeprazole, 1 g of amoxicillin, and 500 mg of clarithromycin, twice daily for 7 days)
Trial: 22066530
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy (5-day dual therapy: 20 mg of rabeprazole and 1 g of amoxicillin, twice daily, followed by 5-day triple therapy: 20 mg of rabeprazole, 500 mg of clarithromycin, and 500 mg of metronidazole, twice daily)
Trial: 9255221
Drug: Insulin-like growth
RxNorm normalized name: Insulin-like growth factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-like growth factor I (IGF-I)
Trial: 12127431
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg lamivudine daily for 4 weeks
Trial: 12127431
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg lamivudine daily for 4 weeks
Trial: 12127431
Drug: Previous lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Previous lamivudine treatment
Trial: 12127431
Drug: Naive to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naive to lamivudine treatment
Trial: 10198369
Drug: Subcutaneous IGF-I,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous IGF-I, 50 microgram/kg/day
Trial: 7786592
Drug: platinum-based combination
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: platinum-based combination chemotherapy with or without doxorubicin (DX)
Trial: 395854
Drug: Bupivacaine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine (mean dose 130 mg)
Trial: 395854
Drug: Pethidine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pethidine (mean dose 183.3 mg)
Trial: 26001561
Drug: Monthly oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly oral ibandronate 100 mg
Trial: 26001561
Drug: Monthly intravenous
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly intravenous ibandronate 1 mg
Trial: 24113041
Drug: Simvastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (40 mg/d) plus Policosanol (20 mg/d)
Trial: 24113041
Drug: Simvastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (40 mg/d) plus Placebo (20 mg/d)
Trial: 17873142
Drug: Oral nicorandil
RxNorm normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nicorandil (15 mg/d) - Group A
Trial: 10216812
Drug: Diltiazem (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (60 mg single dose)
Trial: 10216812
Drug: Diltiazem (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (60 mg repeated doses three times a day for six days and 60 mg on the seventh day)
Trial: 7598923
Drug: Droperidol 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol 0.5 mg with morphine
Trial: 7598923
Drug: Droperidol 1
RxNorm normalized name: droperidol 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol 1 mg with morphine
Trial: 7352669
Drug: Midazolam maleate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam maleate, 10 mg (95% confidence limits: 9-12 mg)
Trial: 7352669
Drug: Sodium thiopental,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium thiopental, 200 mg
Trial: 22468985
Drug: Multimodal, nondrug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal, nondrug therapy (motor stimulation, activities of daily living, cognitive stimulation) for 6 months, 2 hours, 6 days a week
Trial: 18513418
Drug: Statistical methods
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statistical methods for evaluating treatment effect from an RCT with a recurrent outcome
Trial: 12869856
Drug: Cimetidine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (50 mg/hr) for 48 hours after aminophylline infusion
Trial: 10500017
Drug: Tomato oleoresin
RxNorm normalized name: Tomato
DrugBank: Tomato (DB10573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tomato oleoresin (70-75 mg lycopene)
Trial: 10500017
Drug: Lycopene beadlets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lycopene beadlets (70-75 mg lycopene)
Trial: 7570895
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of edrophonium and 3,4-diaminopyridine
Trial: 1721516
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline prepared in hydroxyethylstarch solution (HS-HES, n = 15)
Trial: 1721516
Drug: 6% HES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% HES 200/0.5 solution (6% HES; n = 15)
Trial: 15337874
Drug: Heparin administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin administration
Trial: 31775669
Drug: Progesterone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progesterone (200 mg) plus pessary
Trial: 31775669
Drug: Progesterone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progesterone (200 mg) alone
Trial: 18950837
Drug: Thalidomide 300
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Thalidomide 300 mg daily for 24 months
Trial: 16714251
Drug: Hormone Replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone Replacement Therapy (HRT), given orally.
Trial: 11725694
Drug: DION (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DION (300 mg androstenedione, 150 mg dehydroepiandrosterone, 540 mg saw palmetto, 300 mg indole‐3‐carbinol, 625 mg chrysin, and 750 mg Tribulus terrestris per day)
Trial: 7965657
Drug: 8-mg ondansetron
RxNorm normalized name: ondansetron 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-mg ondansetron tablet
Trial: 7965657
Drug: 8-mg ondansetron
RxNorm normalized name: ondansetron 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-mg ondansetron tablet after a standard meal
Trial: 7965657
Drug: 8-mg ondansetron
RxNorm normalized name: ondansetron 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-mg ondansetron tablet with magnesium hydroxide/aluminum hydroxide antacid
Trial: 31900603
Drug: PF-06342674 (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06342674 (1, 3, 8 mg/kg/q2w or 6 mg/kg/q1w)
Trial: 30641142
Drug: YH4808 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YH4808 (100 mg)
Trial: 30641142
Drug: YH4808 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YH4808 (200 mg and 400 mg)
Trial: 18045737
Drug: Cold saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold saline solution (4 degrees C, 39.2 degrees F)
Trial: 18045737
Drug: Room temperature
RxNorm normalized name: ROOM DEODORIZER POWDER MENTOR #3202
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Room temperature saline solution (23 degrees C, 73.4 degrees F)
Trial: 15332212
Drug: Furosemide (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (25 mg/kg/d intravenously or 35 mg/kg/d orally)
Trial: 8491238
Drug: Metoprolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (100 mg oral dose) during pregnancy
Trial: 3545842
Drug: Urokinase 2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urokinase 2000 IU kg‐1 h‐1 for 24 hours + heparin
Trial: 3545842
Drug: Urokinase 4400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urokinase 4400 IU kg‐1 h‐1 for 12 hours + heparin
Trial: 18030175
Drug: estradiol valerate
RxNorm normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: estradiol valerate (2 mg daily)
Trial: 18030175
Drug: estradiol valerate
RxNorm normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: estradiol valerate in combination with testosterone undecanoate (40 mg every 2 days)
Trial: 23870189
Drug: Ketamine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 0.5 mg/kg and propofol 1-2.5 mg/kg
Trial: 23870189
Drug: Saline 0.9%
RxNorm normalized name: CVS Saline 0.9% Nasal Mist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline 0.9% and propofol 1-2.5 mg/kg
Trial: 16802852
Drug: BIBN 4096
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIBN 4096 BS (single intravenous 10-minute infusion at different dose levels ranging from 0.25 to 10 mg)
Trial: 12966321
Drug: Ethanol (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (0.3 g/kg for men, 0.2 g/kg for women)
Trial: 8638838
Drug: Stellate ganglion
RxNorm normalized name: Mastocarpus stellatus extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stellate ganglion block with 7 ml 1% mepivacaine (n = 10)
Trial: 8638838
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with 7 ml saline (n = 5)
Trial: 8638838
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection with 7 ml mepivacaine into the left deltoid muscle (n = 5)
Trial: 1282218
Drug: Synthetic substance
RxNorm normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic substance P (SP) at doses of 0.5, 1, or 1.5 pmol/kg‐1/min‐1 over 60 min
Trial: 1282218
Drug: Synthetic substance
RxNorm normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic substance P (SP) at 1.5 pmol/kg‐1/min‐1 after pretreatment with sodium valproate (200 mg 16, 8 and 1 h before the SP test)
Trial: 1282218
Drug: Synthetic substance
RxNorm normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic substance P (SP) at the lowest dose (0.5 pmol/kg‐1/min‐1)
Trial: 28506776
Drug: Tai Chi
RxNorm normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tai Chi or physical therapy exercise (12 weeks, twice per week)
Trial: 23936951
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human erythropoietin (rHuEPO) and aggressive intravenous iron therapy
Trial: 20825123
Drug: Bilateral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral treatment of equal intensity
Trial: 8666002
Drug: 447C88 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 447C88 200 mg single dose
Trial: 8666002
Drug: 447C88 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 447C88 800 mg single dose
Trial: 8666002
Drug: 447C88 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 447C88 200 mg twice daily for 10 days
Trial: 31995557
Drug: Vaginal progesterone
RxNorm normalized name: progesterone Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal progesterone (200mg daily self-administered suppository)
Trial: 26151178
Drug: Loading dose
RxNorm normalized name: NUZYRA 7-Day Oral Pack including loading dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose of 50,000 IU VTD3, followed by 25,000 IU at Week 4 and Week 8
Trial: 26151178
Drug: Loading dose
RxNorm normalized name: NUZYRA 7-Day Oral Pack including loading dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose of 100,000 IU VTD3, followed by 50,000 IU at Week 4 and Week 8
Trial: 26151178
Drug: Loading dose
RxNorm normalized name: NUZYRA 7-Day Oral Pack including loading dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose of 200,000 IU VTD3, followed by 100,000 IU at Week 4 and Week 8
Trial: 21453832
Drug: Atorvastatin 80
RxNorm normalized name: atorvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 80 mg (TNT trial)
Trial: 21453832
Drug: Atorvastatin 10
RxNorm normalized name: atorvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10 mg (TNT trial)
Trial: 21453832
Drug: Atorvastatin 80
RxNorm normalized name: atorvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 80 mg/day (IDEAL trial)
Trial: 21453832
Drug: Simvastatin 20
RxNorm normalized name: simvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg/day (IDEAL trial)
Trial: 21453832
Drug: Atorvastatin 80
RxNorm normalized name: atorvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 80 mg/day (SPARCL trial)
Trial: 16705843
Drug: Western routine
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western routine medical treatment (control)
Trial: 9266448
Drug: Intra-arterial carboplatin
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial carboplatin chemotherapy at a dose escalated to 1400 mg/hemisphere
Trial: 9266448
Drug: Intra-arterial carboplatin
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial carboplatin chemotherapy
Trial: 29497759
Drug: Computer-based writing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-based writing treatment
Trial: 21496516
Drug: Acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance and Commitment Therapy (ACT) bibliotherapy, Japanese translation of a self-help book, duration: 2 months reading period followed by a 2-month follow-up.
Trial: 17196044
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese Medicine (TCM)‐style acupuncture with manual stimulation for depression
Trial: 10693157
Drug: Ketamine (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.3 mg/kg i.v.)
Trial: 3523664
Drug: Enprofylline (14.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enprofylline (14.1 mg/kg/day)
Trial: 3523664
Drug: Theophylline (16.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (16.2 mg/kg/day)
Trial: 31567764
Drug: Butorphanol 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butorphanol 0.1 mg (group I)
Trial: 31567764
Drug: Butorphanol 1
RxNorm normalized name: butorphanol 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butorphanol 1 mg (group II)
Trial: 9593078
Drug: Fluvastatin, 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin, 40 mg once daily
Trial: 9593078
Drug: Pravastatin, 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin, 40 mg once daily
Trial: 7640154
Drug: Intranasal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal administration of 1.0 mg clonazepam
Trial: 7640154
Drug: Buccal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Buccal administration of 1.0 mg clonazepam
Trial: 7640154
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of 0.5 mg clonazepam
Trial: 2663163
Drug: guaimesal (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: guaimesal (500 mg, three times daily for seven days)